Published in final edited form as:

Chem Res Toxicol. 2010 June 21; 23(6): 1089–1096. doi:10.1021/tx100062v.

Detection of 7-(2'-Carboxyethyl)guanine but not 7-Carboxymethylguanine in Human Liver DNA

Guang Cheng, Mingyao Wang, Peter W. Villalta, and Stephen S. Hecht*

Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455

Abstract

7-Carboxymethylguanine (7-CMGua) and 7-(2'-carboxyethyl)guanine (7-CEGua) are DNA adducts that potentially could be formed upon metabolism of the carcinogenic nitrosamines *N*-nitrososarcosine (NSAR) and 3-(methylnitrosamino)propionic acid (MNPA), respectively, or from other sources such as nitrosation of glycine (7-CMGua) or reaction of DNA with acrylic acid (7-CEGua). Since both NSAR and MNPA have been detected in human urine, and there are plausible sources of exposure to other precursors to these adducts, we analyzed human liver DNA for 7-CMGua and 7-CEGua, using liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring (LC-ESI-MS/MS-SRM). Human hepatic DNA was mixed with [¹⁵N₅]7-CMGua and [¹⁵N₅]7-CEGua as internal standards and enzymatically hydrolyzed. The hydrolysate was partially purified by solid-phase extraction and the resulting fraction was treated with acetyl chloride in methanol to convert 7-CMGua and 7-CEGua to their methyl esters. After a second solid-phase extraction, LC-ESI-MS/MS-SRM analysis was carried out using the transitions m/z 224 $[M + H]^+ \rightarrow m/z$ 164 $[(M + H) - HCOOCH_3]^+$ and m/z 238 $[M + H]^+ \rightarrow m/z$ 152 $[BH]^+$ for the methyl esters of 7-CMGua and 7-CEGua, respectively. The method was sensitive, accurate, precise, and apparently free from artifact formation. 7-CEGua, as its methyl ester, was detected in all 24 human liver samples analyzed, mean $\pm$ S.D., 373 ± 320 fmol/ μ mol Gua (74.6 adducts per 10^9 nucleotides), range 17–1189 fmol/ μ mol Gua, but the methyl ester of 7-CMGua was not detected in any sample. These results demonstrate the ubiquitous presence of 7-CEGua in human liver DNA. Acrylic acid may be a likely endogenous precursor to 7-CEGua.

Introduction

The ability of DNA adducts to induce mutations has been clearly demonstrated in multiple studies (1). When these mutations occur in critical regions of important genes such as *ras* and *p53*, the result can be loss of normal cellular growth control mechanisms, genomic instability, and cancer (2–4). By characterizing DNA adducts in human tissues and establishing their miscoding potential, new leads for understanding cancer etiology can potentially be obtained.

In this study, we focused on the analysis of 7-carboxymethylguanine (7-CMGua, **5**, Scheme 1) and 7-(2'-carboxyethyl)guanine (7-CEGua, **13**). These adducts could potentially be formed from the carcinogenic nitrosamines *N*-nitrososarcosine (NSAR, **1**) and 3-(methylnitrosamino)propionic acid (MNPA, **10**). NSAR causes esophageal tumors in rats, nasal tumors in Swiss mice, and liver tumors in newborn mice (5). The major sources of human exposure to NSAR are believed to be consumption of smoked and cured meats, and endogenous formation (5,6). NSAR has been consistently detected in human urine (6).

*To whom correspondence should be addressed: Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware St SE, Minneapolis, MN 55455, USA. phone: (612) 624-7604 fax: (612) 626-5135 hecht002@umn.edu.

Levels of NSAR in the urine of healthy individuals averaged 0.42 and 0.94 $\mu\text{g/day}$ in two studies in Germany, 0.36 $\mu\text{g/day}$ in the United Kingdom, 0.1 $\mu\text{g/day}$ in Poland, 3.4 $\mu\text{g/day}$ in Egypt, and 0.1–1.5 $\mu\text{g/day}$ in China. Increased levels were found in regions of high esophageal cancer incidence in China and high gastric cancer incidence in Poland (6). NSAR is “reasonably anticipated to be a human carcinogen” according to the U.S. Dept. of Health and Human Services (7).

Although 88% of NSAR is excreted unchanged in rats (8), its carcinogenicity strongly indicates that it is metabolized to some extent. Cytochrome P450 catalyzed metabolism of NSAR by hydroxylation of its methyl group, a well established and common metabolic pathway for *N*-methyl-*N*-nitroso compounds (9), is expected to yield the unstable intermediate α -hydroxymethylNSAR (2). Intermediate 2 will spontaneously eject formaldehyde with the formation of the carboxymethyl diazonium ion 3, which exists in equilibrium with diazotate 4. Multiple studies have demonstrated that this intermediate, generated from various sources, is a carboxymethylating agent and reacts with DNA to produce 7-CMGua as well as O^6 -CMGua (6). Thus, Zurlo et al demonstrated that 7-CMGua was formed in pancreatic acinar cells exposed to azaserine (7)(10). The Shuker group carried out a series of studies investigating the formation of O^6 -CMGua. They demonstrated that the nitrosated bile acid conjugate *N*-nitrosoglycocholic acid (8) and related *N*-nitroso-compounds produced 7-CMGua and O^6 -CMGua (as well as O^6 -methylGua) in vitro (11,12). They also showed that O^6 -CMGua could be formed upon nitrosation of glycine (9) in vitro, presumably via intermediate 4, and detected O^6 -CMGua in three human blood samples using an immunoslot blot assay (13). Using immunohistochemistry techniques, they demonstrated positive staining of exfoliated colonic cells for O^6 -CMGua, and this staining was significantly higher in cells from humans who consumed a high red meat diet (14). Further studies demonstrated that potassium diazotate, a stable precursor to 4, produced mutations in the *p53* gene in vitro (15).

MNPA is a relatively weak inducer of lung adenomas in A/J mice in the one reported study of its carcinogenicity (16). The greatest known source of human exposure to MNPA is smokeless tobacco which contains substantial amounts of this nitrosamine (17). MNPA has been reported in human urine at levels of 0.1 – 0.4 $\mu\text{g/day}$ in studies of healthy individuals on normal diets (18). Its levels were higher in areas of Poland where inhabitants have a relatively high risk for stomach cancer compared to low risk areas (18,19). It is not clear whether the occurrence of MNPA in human urine is related to tobacco use. α -Methyl hydroxylation of MNPA would produce intermediate 11 which upon loss of formaldehyde yields the carboxyethyl diazonium ion 12. This intermediate would be expected to react with DNA to produce 7-CEGua (13). 7-CEGua has been previously detected in liver DNA of rats treated with the hepatocarcinogen 1-nitroso-5,6-dihydrouracil (14)(20). 7-CEGua is also formed in the reactions of acrylic acid (16) and β -propiolactone (17) with DNA in vitro (21).

Collectively, these data provided a strong rationale for investigating the presence of 7-CMGua and 7-CEGua in human DNA. Therefore, we used liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring (LC-ESI-MS/MS-SRM) to analyze human liver DNA for these adducts.

Experimental Procedures

HPLC-UV Analysis

This was carried out using Waters Associates (Milford, MA) instruments equipped with a model 996 Photodiode array detector for system 1 and a Shimadzu SPD-10A UV detector (Shimadzu Scientific Instruments, Columbia, MD) for system 2. The UV detector was operated at 254 nm. System 1 used a 10 mm $\times$ 25 cm 5 μm Luna C18 column (Phenomenex,

Torrance, CA) with a gradient from 5% CH₃OH in 0.35% aq formic acid to 40% CH₃OH over the course of 35 min at a flow rate of 3.3 mL/min. This system was used for collecting 7-CMGua, [¹⁵N₅]7-CMGua, 7-CEGua, and [¹⁵N₅]7-CEG. System 2 used a 4.6 mm × 25 cm Luna 5μ C18 column with a gradient from 5 to 40 % CH₃OH in H₂O over the course of 35 min at a flow rate of 0.7 mL/min. This system was used for quantitation of dGuo or Gua in DNA samples. Results from the two methods agreed within 5%. The Gua values reported here were calculated from measured dGuo.

Chemicals, Enzymes, and Chromatography Supplies

[¹⁵N₅]dGuo was purchased from Spectra Stable Isotopes (Columbia, MD). Ethanol was obtained from AAPER Alcohol and Chemical Co. (Shelbyville, KY). 2-Propanol was procured from ACROS Organics (Morris Plains, NJ). Puregene DNA purification solution was obtained from Qiagen (Morris Plains, NJ). Oasis MCX 3 cc, 60 mg LP Extraction cartridges were obtained from Waters (Milford, MA). Strata-X cartridges (33 μm, 30 mg/1 mL) were obtained from Phenomenex. Alkaline phosphatase was purchased from Roche Diagnostic Corp (Indianapolis, IN). N²-(1'-Carboxyethyl)deoxyguanosine was prepared essentially as described (22). All other chemicals and enzymes were obtained from Sigma-Aldrich (St. Louis, MO).

7-Carboxymethylguanine (7-CMGua, 5) and [¹⁵N₅]7-CMGua

7-CMGua was prepared as described by Zurlo et al (10) with minor modifications. Iodoacetic acid (238.6 mg, 1.3 mmol) and Guo (92.2 mg, 0.33 mmol) were dissolved in 600 μL of H₂O containing 16.3 mg LiOH. The mixture was heated at 100 °C for 70 min. The color of the solution turned to brownish red. The product was purified using HPLC system 1. ¹H NMR : δ8.25 (bs, 1H, N1H), 7.66 (s, 1H, C8H), 6.00 (s, 2H, NH₂), 4.46 (s, 2H, CH₂); positive ESI-MS: *m/z* 210 [M + H]⁺, MS/MS of *m/z* 210, *m/z* 152 [BH]⁺; UV λ_{max} 252 nm, λ_{min} 230.

[¹⁵N₅]7-CMGua was prepared from [¹⁵N₅]dGuo using the same procedure. positive ESI-MS: *m/z* 215 [M + H]⁺, MS/MS of *m/z* 215, *m/z* 157 [BH]⁺.

The concentration of 7-CMGua in standard solutions was determined by ¹H NMR using toluene as internal standard, as previously described (23) The concentration of [¹⁵N₅]7-CMG was determined by UV at 254 nm.

7-(2'-Carboxyethyl)guanine (7-CEGua, 13) and [¹⁵N₅]7-CEGua

7-CEGua was prepared essentially as described above. Iodopropionic acid (240 mg, 1.2 mmol) and dGuo (80 mg, 0.3 mmol) were dissolved in 1mL of dimethylacetamide and the mixture was stirred at room temperature overnight, then heated at 100 °C for 5 h. The product was purified by HPLC using system 1. ¹H NMR δ 8.23(bs, 1H, N1H), 7.79 (s, 1H, C8H), 6.11 (s, 2H, NH₂), 4.28 (t, 2H, CH₂CH₂COOH), 2.74 (t, 2H, CH₂CH₂COOH); positive ESI-MS *m/z* 224 [M + H]⁺, MS/MS of *m/z* of 224, *m/z* 152 [BH]⁺; UV λ_{max} 250 nm, λ_{min} 233 nm. [¹⁵N₅]7-CEG was prepared from [¹⁵N₅]dGuo using the same procedure. positive ESI-MS *m/z* 229 [M + H]⁺, MS/MS of *m/z* of 229, *m/z* 157 [BH]⁺

The concentrations of 7-CEGua and [¹⁵N₅]7-CEGua in standard solutions were determined by ¹H NMR and UV at 254 nm, respectively.

7-(1'-Carboxyethyl)guanine (18)

This was prepared as described for 7-CEGua from 2-bromopropionic acid and dGuo followed by heating at 100 °C for 5h; positive ESI-MS *m/z* 224 [M + H]⁺, MS/MS of *m/z* of 224, *m/z* 152 [BH]⁺; UV λ_{max} 250 nm, λ_{min} 233 nm.

Human liver samples and DNA isolation

This study was approved by the University of Minnesota Research Subjects' Protection Program Institutional Review Board Human Subjects Committee. Twenty-four de-identified liver samples were obtained through The Masonic Cancer Center Tissue Procurement Facility. The samples were removed during surgery, immediately frozen in liquid N₂, confirmed histopathologically as normal, and stored at -80 °C.

DNA isolation was performed as previously described with minor modifications (24). Briefly, the liver samples (0.5 g) were homogenized with 15 mL of cell lysis solution. After the samples were treated with RNase A and protein was precipitated, DNA was precipitated with 2-propanol. The DNA was dissolved in 4 mL of 10 mM Tris-HCl/1 mM EDTA buffer (pH 7), and the mixture was extracted twice with CHCl₃ containing 4% isoamyl alcohol. The DNA was precipitated by addition of 5 M NaCl and ice-cold ethanol, and washed with 70% and 100% ethanol.

For experiments using *N*-acetylcysteine to investigate artifactual formation of 7-CEGua, 10 mM *N*-acetylcysteine was added to the cell lysis solution before the tissue was homogenized. The DNA was isolated as described above.

Analysis of DNA for 7-CMGua and 7-CEGua

The procedure for enzymatic hydrolysis of DNA was previously described (25). In brief, DNA (1 mg) was dissolved in 1 mL of 10 mM Tris-HCl/5 mM MgCl₂ buffer (pH 7.0) containing [¹⁵N₅]7-CMGua (1920 fmol) and [¹⁵N₅]7-CEGua (1040 fmol). The DNA was enzymatically hydrolyzed for 70 min at 37 °C with 1060 units of DNase I (type II, bovine pancreas), 0.05 units of phosphodiesterase I (type II, *Crotalus adamanteus* venom), and 300 units of alkaline phosphatase (calf intestine). The hydrolysate, after removal of a 10 µL aliquot for dGuo quantitation, was purified using a mixed mode cation exchange (MCX Vac RC, 60 mg, Waters) cartridge. The cartridge was conditioned with 2 mL of CH₃OH and 2 mL 2% H₃PO₄. The sample, which had been acidified with 10 µL 86% H₃PO₄, was loaded and the column was washed with 2 mL 0.1% H₃PO₄ and 2 mL of CH₃OH, which were discarded. It was then washed with 2 mL 3% NH₄OH in CH₃OH. This fraction was collected and evaporated to dryness on a SpeedVac. To the vial was added 1 mL freshly prepared 10% CH₃COCl in CH₃OH, and the mixture was heated for 1 h at 50 °C, then concentrated to dryness. The residue was dissolved in 1 mL 15 mM NH₄OAc buffer (pH 6.6) and purified using a Strata-X (33 µm, 30 mg/1 mL, Phenomenex) solid-phase extraction cartridge. The cartridge was conditioned with 1 mL CH₃OH, 1 mL H₂O and 1 mL 15 mM NH₄OAc buffer (pH 6.6). The sample was loaded on the cartridge which was washed with 1 mL 15 mM NH₄OAc buffer (pH 6.6), 1 mL H₂O, and 1 mL 2% aq. CH₃OH. It was then washed with 1 mL of 80% CH₃OH, and this eluant was collected and evaporated to dryness. The residue was dissolved in 40 µL of 15 mM NH₄OAc buffer (pH 6.6), and 8 µL aliquots were analyzed by LC-ESI-MS/MS-SRM.

The analysis was carried out with either a Quantum Ultra AM (with Ion Max ESI source) or Discovery Max triple quadrupole mass spectrometer (Thermo Scientific, San Jose, CA) interfaced with an Agilent Technologies (Palo Alto, CA) 1100 capillary flow HPLC equipped with a 150 mm × 0.5 mm Zorbax SB C18 column (Agilent). The column was operated at 50 °C and eluted with a gradient from 5% to 25% CH₃CN in 15 mM NH₄OAc buffer (pH 6.6) for 10 min, then a gradient from 25–80% CH₃CN in 2 min, then held at 80% for 6 min, and finally returning to 5% CH₃CN in 2 min, at a flow rate of 15 µL/min. The first 2 min of eluant was directed to waste, and the 2–15 min fractions were diverted to the ESI source, then the remaining 5 min eluant to waste.

A second HPLC system was used for confirmation of identity. A 150 mm × 0.5 mm, 4 μm, Synergi Polar-RP column (Phenomenex) was eluted with a gradient from 5 to 35% CH₃OH in 15 mM NH₄OAc buffer (pH 6.6) in 35 min at a flow rate of 10 μL/min at 50 °C. The first 15 min of eluant was directed to waste, and the 15 to 35 min fraction was diverted to the ESI source.

The MS parameters were set as follows: spray voltage, 4 kV; sheath gas pressure, 30; capillary temperature, 250 °C; collision energy, 22 V; scan width, 0.1 amu; scan time, 0.4 s; Q1 peak width, 0.7; Q3 peak width, 0.7; Q2 pressure, 1.0 mTorr; source CID, 8V; and tube lens offset, 95V. Transitions monitored were as follows, for the methyl esters of 7-CMGua, [¹⁵N₅]7-CMGua, 7-CEGua and [¹⁵N₅]7-CEGua, respectively: m/z 224 [M + H]⁺ → m/z 164 [(M + H) - HCOOCH₃]⁺; m/z 229 [M + H]⁺ → m/z 169 [(M + H) - HCOOCH₃]⁺; m/z 238 [M + H]⁺ → m/z 152 [BH]⁺; and m/z 243 [M + H]⁺ → m/z 157 [BH]⁺.

Calibration curves were constructed before each analysis using standard solutions of 7-CEGua and [¹⁵N₅]7-CEGua. A constant amount of [¹⁵N₅]7-CEGua (1040 fmol) was mixed with differing amounts of 7-CEGua (20, 40, 80, 160, 320, and 640 fmol), and these were esterified with CH₃COCl and CH₃OH and analyzed by LC-ESI-MS/MS-SRM. Each set of human liver samples contained negative (buffer blanks) and positive (calf thymus DNA samples) controls.

Accuracy and precision were determined by adding 20, 40, 80, 160, or 320 fmol of 7-CEGua in triplicate to 0.5 mg aliquots of calf thymus DNA and analyzing each sample in duplicate. The amount of 7-CEGua which was present in calf thymus DNA (52 fmol/ 0.5 mg) was subtracted from the amount detected. Recovery was determined by adding 1040 fmol of [¹⁵N₅]7-CEGua to 0.5 mg of calf thymus DNA and processing as described above. The results were compared to the same analysis without solid-phase extraction.

Effects of *N*-acetylcysteine on formation of 7-CEGua in reactions of acrylic acid with dGuo and calf thymus DNA

A mixture of dGuo (30 mg, 110 μmol), acrylic acid (0.32 mg, 4.5 μmol), and *N*-acetylcysteine (final concentration 0, 1, 2, 5 or 10 mM) in 15 mL of 0.1M phosphate buffer, pH 7, was incubated at 37 °C for 24 h in a shaking water bath. The resulting mixture was analyzed as described above for 7-CEGua. Reactions with calf thymus DNA (30 mg) were carried out and analyzed in a similar fashion.

Effects of *N*-acetylcysteine on levels of 7-CEGua in human liver DNA

N-Acetylcysteine (final concentration, 10mM) was added to the cell lysis solution before homogenizing the tissue, and DNA was isolated and analyzed as described above.

Results

The internal standards, [¹⁵N₅]7-CMGua and [¹⁵N₅]7-CEGua, were prepared by reactions of iodoacetic acid and 3-iodopropionic acid, respectively, with [¹⁵N₅]dGuo, followed by neutral thermal hydrolysis. We also prepared adducts **18** and **19**, which could have interfered with the analysis of 7-CMGua and 7-CEGua. Adduct **18** was prepared by the reaction of dGuo with 2-bromopropionic acid followed by neutral thermal hydrolysis and adduct **19** by reaction of methylglyoxal with dGuo (22).

Since 7-CMGua and 7-CEGua would be released from DNA by neutral thermal hydrolysis due to the lability of the Gua N⁹-deoxyribose 1' bond, our initial plan was to use neutral thermal hydrolysis followed by solid-phase extraction to enrich the adducts. This was not successful because neutral thermal hydrolysis produced a relatively high background in the LC-ESI-MS/MS-SRM analysis of these adducts. Experimentation with calf thymus DNA (which contains 7-CEGua) showed that enzyme hydrolysis was superior to neutral thermal hydrolysis or the combination of both methods of hydrolysis in the release of 7-CEGua from DNA because it produced the highest signal to noise ratio in the LC-ESI-MS/MS-SRM analysis.

Solid-phase extraction of 7-CMGua and 7-CEGua using mixed mode cation exchange cartridges was successful, but we were unable to achieve good results with Strata-X reverse phase cartridges. Since both enrichment steps were necessary and the high polarity of the adducts was suspected to be a reason for their poor retention on Strata-X columns, we converted 7-CMGua and 7-CEGua to their methyl esters by treatment with CH₃COCl and MeOH.

The analytical method is summarized in Scheme 2. Human hepatic DNA and the internal standards were subjected to enzyme hydrolysis followed by solid-phase extraction using mixed mode cation exchange cartridges. The adducts were converted to their methyl esters **20** and **21**, which proceeded in 90% yield, and the resulting mixture was purified by solid-phase extraction on Strata-X cartridges. The appropriate fraction was collected and analyzed by LC-ESI-MS/MS-SRM at m/z 224 [M + H]⁺ → m/z 164 [M – HCOOCH₃]⁺ for **20** and m/z 238 [M + H]⁺ → m/z 152 [BH]⁺ for **21**.

A typical chromatogram obtained upon LC-ESI-MS/MS-SRM analysis using this method is shown in Figure 1. A clear peak for 7-CEGua methyl ester **21** was observed in the m/z 238 → m/z 152 channel, and this peak co-eluted with the corresponding internal standard [¹⁵N₅]7-CEGua methyl ester, monitored at m/z 243 → m/z 157. In contrast, no peak was observed for 7-CMGua methyl ester **20**, in the m/z 224 → m/z 164 channel. Using a different LC column (Synergi Polar-RP) to confirm the presence of 7-CEGua methyl ester **21**, a sharp peak corresponding to **21** was observed, and it co-eluted with the internal standard (Figure 2). The related standards **18** and **19**, as their methyl esters, eluted at retention times different from **21** under the conditions used in Figure 1: 0.1 min later for **18** and 3.6 min later for **19**.

A calibration curve for methyl ester **21** was linear in the range measured (20 – 640 fmol), R² = 1. The accuracy and precision of the method were tested by adding various amounts of 7-CEGua to calf thymus DNA and carrying out the analysis of three aliquots at each added concentration. The results which are summarized in Table 1 demonstrate outstanding accuracy and precision. The on column detection limits for esters **20** and **21** were 10 fmol and 5 fmol, respectively. Recovery was about 50%. The detection limit for **21** in DNA, starting with 1 mg, was approximately 8 fmol.

We considered the possibility that 7-CEGua could be formed as an artifact by reaction of acrylic acid, a ubiquitous compound, with DNA during the isolation and analysis. We investigated this problem by first determining the effects of *N*-acetylcysteine on the reaction

of acrylic acid with dGuo or DNA. As shown in Table 2, *N*-acetylcysteine inhibited this reaction, presumably by scavenging acrylic acid by Michael addition. Maximum inhibition of about 80% was obtained with 10 mM *N*-acetylcysteine. We then analyzed three human liver DNA samples in the absence and presence of 10 mM *N*-acetylcysteine, added at the DNA isolation step. The amounts of **21** detected in these analyses, with or without *N*-acetylcysteine addition were: sample 1, 419 and 414 fmol/μmol Gua; sample 2, 1673 and 1491 fmol/μmol Gua; and sample 3, 177 and 180 fmol/μmol Gua. These results demonstrate that artifact formation was not occurring during isolation of DNA and analysis for 7-CEGua.

The results of the analyses of 24 human liver DNA samples are presented in Table 3. 7-CEGua, as its methyl ester **21**, was detected in all of the samples, mean ± S.D., 373 ± 320 fmol/μmol Gua (74.6 adducts per 10⁹ nucleotides), range 17– 1189 fmol/μmol Gua. 7-CMGua, as its methyl ester **20**, was not detected in any sample. There was no relationship of 7-CEGua levels to age and gender. No information on tobacco use was available.

Discussion

We present convincing evidence for the presence of 7-CEGua in human liver DNA. We monitored the transition m/z 238 $[M + H]^+ \rightarrow m/z$ 152 $[BH]^+$, which is characteristic of our analyte **21**, the methyl ester of 7-CEGua. Our LC-ESI-MS/MSSRM chromatograms showed clear peaks which co-eluted with the internal standard [¹⁵N₅]7-CEGua, as its methyl ester, in two different LC systems (Figures 1 and 2). We found no evidence however for the presence of 7-CMGua in these liver DNA samples, as there were no clear peaks eluting at the retention time of its methyl ester **20**.

As indicated in Scheme 1, there are several possible sources of 7-CEGua (**13**) in human liver DNA. One of the most likely may be reaction of acrylic acid (**16**) with DNA. Acrylic acid is a metabolite of acrolein in the rat, based on in vitro studies with rat liver preparations, and on in vivo studies in which the excretion of the mercapturic acid *N*-acetyl-S-(2-carboxyethyl)cysteine was observed in the urine of rats treated with either acrolein or acrylic acid (26–29). Acrolein is a commonly observed lipid peroxidation product and ubiquitous environmental pollutant, occurring in various types of engine exhaust and industrial emissions (30). It is formed in high temperature cooking and is found in various foods (30,31). Acrolein forms exocyclic adducts with dGuo in DNA, and these have been detected in some human tissues (30,32–39). Acrylic acid is widely employed in the production of acrylates which are used in the manufacturing of polymers, leading potentially to human exposure (40). Mercapturic acid metabolites of acrolein and acrylic acid, *N*-acetyl-S-(3-hydroxypropyl)cysteine and *N*-acetyl-S-(2-carboxyethyl)cysteine, are routinely detected in the urine of non-smokers (41,42). Acrylic acid reacts with DNA in vitro giving 7-CEGua as a product, although the reaction is slow and has not been reported in vivo (21). Nevertheless, these data collectively provide a plausible mechanism for our finding of 7-CEGua in human hepatic DNA.

A second possible source is 1-nitroso-5,6-dihydrouracil (**14**). Favoring this hypothesis is the fact that 7-CEGua has been detected in the hepatic DNA of rats treated with **14**. Therefore, if there is human exposure to **14**, its metabolism to 7-CEGua in the liver is likely. Human exposure to **14** could potentially occur by endogenous nitrosation of 5,6-dihydrouracil (**22**). This is formed in the metabolism of uracil, catalyzed by dihydropyrimidine dehydrogenase. Subsequent steps in the metabolism of uracil lead to β-ureidopropionic acid (**23**) and finally to β-alanine (**24**). Levels of **22** in the urine of healthy volunteers averaged 1.41 μmol/mmol creatinine (about 1 mg per day) while those of **23** and **24** were 2.09 and 0.69 μmol/mmol creatinine, respectively (43). Levels of **22** in plasma of healthy subjects averaged 36 ng/mL plasma (44). Endogenous nitrosation of **22** could potentially occur in situations of high

nitrite exposure or generation of endogenous NO, but this requires further investigation (6,45–47). Nitrosation of **23** and **24** could also lead to carboxyethyl diazonium ion **12**.

Our original hypothesis for this study pertained to the nitrosamines NSAR and MNPA. Although MNPA has not been reported frequently as a constituent of human urine, the levels reported in the one study carried out in Poland were similar to those of NSAR and indicate an environmental or endogenous source of exposure to this nitrosamine in humans (6,18). α -Methyl hydroxylation of MNPA, while apparently not reported in the literature, is certainly a likely route of metabolism of this nitrosamine. Thus, the generation of carboxyethyl diazonium ion **12** in this way is completely reasonable and could be the source of 7-CEGua in hepatic DNA. Arguing against this hypothesis however is the lack of detection of 7-CMGua in our samples. Since, in most studies carried out in Western countries, levels of NSAR reported in human urine are similar to those of MNPA (6), we might have expected to detect both 7-CMGua and 7-CEGua if these nitrosamines were their sources. It is possible however, that NSAR is metabolized to a lesser extent than MNPA by α -methyl hydroxylation. This requires further study.

In view of the extensive studies on O^6 -CMGua formation, we were somewhat surprised to find no evidence for the presence of 7-CMGua in human liver DNA. In vitro reactions of *N*-nitrosoglycocholic acid (**8**) with DNA produced 7-CMGua and O^6 -CMGua in an approximate 10:1 ratio, consistent with data on other alkylating agents (11,48). Other studies by Shuker et al provide convincing evidence for a number of *N*-nitroso compound precursors to O^6 -CMGua in DNA via diazoacetate (**4**), a reaction which also produces O^6 -methylGua via decarboxylation of **4** (12,13). They also reported the presence of this adduct in exfoliated colonic cells obtained from volunteers participating in a diet study to investigate the potential genotoxic effects of *N*-nitroso compounds arising from red meat consumption, an area of research that has been extensively and convincingly documented by the Bingham group (14,49,50). There are no reports in the literature of O^6 -CMGua in hepatic DNA. It is possible that the formation of this adduct is specific to favorable conditions which exist in the colon. Decarboxylation of **4** to O^6 -methylGua might also partially limit the observed levels of 7-CMGua.

The levels of 7-CEGua found in this study (373 fmol/ μ mol Gua) are quite comparable to those of the acetaldehyde DNA adduct N^2 -ethylidene-dGuo (534 fmol/ μ mol dGuo) which we have previously quantified in human hepatic DNA by LC-ESI-MS/MS-SRM (51). 7-CEGua levels were substantially higher than those of 7-ethylGua (42 fmol/ μ mol Gua) (24), N^2 -ethyl-dGuo (21 fmol/ μ mol dGuo) (51), and the 1, N^2 -propano-dGuo adduct of crotonaldehyde and acetaldehyde (ND – 15 fmol/ μ mol dGuo) (52) all quantified in human liver DNA by LC-ESI-MS/MS-SRM. The levels reported here are also higher than those of several endogenous DNA adducts reported in human hepatic DNA analyzed by various methods (53). These results suggest that there is a commonly occurring and rich source of 7-CEGua adducts in hepatic DNA.

There are no reports on the mutagenic properties of 7-CEGua. In general, 7-alkylGua derivatives are not considered to be mutagenic per se. However, they are prone to depurination, which can lead to abasic sites in DNA (54). If these are not repaired, the result can be G $\rightarrow$ T mutations and other changes (54,55).

Our finding of 7-CEGua in human hepatic DNA raises significant questions regarding its source and the potential role of its precursors in human carcinogenesis. It will be important to determine whether acrylic acid, endogenous nitrosation of 5,6-dihydrouracil or glycine, or another mechanism is its main source. Another consideration, not addressed in this study, is tobacco use. These questions cannot be answered by assaying for this adduct in hepatic DNA because liver tissue is not routinely available. Therefore, we are investigating the detection of this adduct in human leukocyte DNA or urine.

A limitation of this study is that we do not know to what extent depurination of 7-CMGua or 7-CEGua may take place during DNA isolation, before the addition of the internal standards. If depurination does occur during DNA isolation, the values reported here would be lower than actually exist in hepatic DNA. A solution to this would be the synthesis of a DNA strand containing [¹⁵N]7-CEDGuo, which could be added at the beginning of the DNA isolation procedure.

In summary, we report the detection of substantial amounts of 7-CEGua in human hepatic DNA. The related adduct, 7-CMGua, was not detected. These results provide some new insights on possible mechanisms of DNA damage in humans. While our original hypothesis involved the possible production of these adducts from *N*-nitroso compounds, our results suggest that acrylic acid may be a more likely precursor.

Acknowledgments

This study was supported by grant CA-85702 from the National Cancer Institute. We thank Li Chen for her contributions to this study and Bob Carlson for editorial assistance.

References

1. Delaney JC, Essigmann JM. Biological properties of single chemical-DNA adducts: a twenty year perspective. *Chem. Res. Toxicol.* 2008; 21:232–252. [PubMed: 18072751]
2. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. *Oncogene.* 2002; 21:7435–7451. [PubMed: 12379884]
3. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer.* 2001; 92:1525–1530. [PubMed: 11745231]
4. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature.* 2001; 410:1111–1116. [PubMed: 11323676]
5. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol. vol. 17. IARC; Lyon, FR: 1978. Some *N*-nitroso compounds; p. 83-124.
6. Tricker AR. *N*-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. *Eur. J. Cancer Prev.* 1997; 6:226–268. [PubMed: 9306073]
7. U.S.Department of Health and Human Services. 10th Report on Carcinogens. 2002
8. Ohshima H, Bereziat JC, Bartsch H. Monitoring *N*-nitrosamine acids excreted in the urine and feces of rats as an index for endogenous nitrosation. *Carcinogenesis.* 1982; 3:115–120. [PubMed: 6175434]
9. Preussmann, R.; Stewart, BW. *N*-Nitroso Carcinogens. In: Searle, CE., editor. *Chemical Carcinogens, Second Edition, ACS Monograph 182.* Vol. vol. 2. American Chemical Society; Washington, DC: 1984. p. 643-828.

10. Zurlo J, Curphey TJ, Hiley R, Longnecker DS. Identification of 7-carboxymethylguanine in DNA from pancreatic acinar cells exposed to azaserine. *Cancer Res.* 1982; 42:1286–1288. [PubMed: 7060007]
11. Shuker DE, Margison GP. Nitrosated glycine derivatives as a potential source of O⁶-methylguanine in DNA. *Cancer Res.* 1997; 57:366–369. [PubMed: 9012456]
12. Harrison KL, Jukes R, Cooper DP, Shuker DEG. Detection of concomitant formation of O⁶-carboxymethyl- and O⁶-methyl-2'-deoxyguanosine in DNA exposed to nitrosated glycine derivatives using a combined immunoaffinity/HPLC method. *Chem. Res. Toxicol.* 1999; 12:106–111. [PubMed: 9894025]
13. Cupid BC, Zeng Z, Singh R, Shuker DE. Detection of O⁶-carboxymethyl-2'-deoxyguanosine in DNA following reaction of nitric oxide with glycine and in human blood DNA using a quantitative immunoslot blot assay. *Chem. Res. Toxicol.* 2004; 17:294–300. [PubMed: 15025499]
14. Lewin MH, Bailey N, Bandaletova T, Bowman R, Cross AJ, Pollock J, Shuker DE, Bingham SA. Red meat enhances the colonic formation of the DNA adduct O⁶-carboxymethyl guanine: implications for colorectal cancer risk. *Cancer Res.* 2006; 66:1859–1865. [PubMed: 16452248]
15. Gottschalg E, Scott GB, Burns PA, Shuker DE. Potassium diazoacetate-induced *p53* mutations *in vitro* in relation to formation of O⁶-carboxymethyl- and O⁶-methyl-2'-deoxyguanosine DNA adducts: relevance for gastrointestinal cancer. *Carcinogenesis.* 2007; 28:356–362. [PubMed: 16926174]
16. Rivenson A, Djordjevic MV, Amin S, Hoffmann D. Bioassay in A/J mice of some N-nitrosamines. *Cancer Lett.* 1989; 47:111–114. [PubMed: 2636026]
17. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. v. 89. IARC; Lyon, FR: 2007. Smokeless tobacco and tobacco-specific nitrosamines; p. 41-417.
18. Zatonski W, Ohshima H, Przewozniak K, Drosik K, Mierzwinska J, Krygier M, Chmielarczyk W, Bartsch H. Urinary excretion of N-nitrosamino acids and nitrate by inhabitants of high- and low-risk areas for stomach cancer in Poland. *Int. J. Cancer.* 1989; 44:823–827. [PubMed: 2583863]
19. Forman D, Al Dabbagh S, Knight T, Doll R. Nitrate exposure and the carcinogenic process. *Ann. N. Y. Acad. Sci.* 1988; 534:597–603. [PubMed: 3291717]
20. Mirvish SS, Ross AE, Gold B, Drake N. In vitro and in vivo formation of 7-(2'-carboxyethyl)guanine from the liver carcinogen 1-nitroso-5,6-dihydrouracil and its reactions with water and methanol. *J Natl. Cancer Inst.* 1985; 74:1105–1110. [PubMed: 2582174]
21. Solomon, JJ. DNA adducts of lactones, sultones, acylating agents and acrylic compounds. In: Hemminki, K.; Dipple, A.; Shuker, DEG.; Kadlubar, FF.; Segerbäck, D.; Bartsch, H., editors. *DNA Adducts: Identification and Biological Significance*. International Agency for Research on Cancer; Lyon: 1994. p. 179-198.
22. Synold T, Xi B, Wuenschell GE, Tamae D, Figarola JL, Rahbar S, Termini J. Advanced glycation end products of DNA: quantification of N² - (1-carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. *Chem Res Toxicol.* 2008; 21:2148–2155. [PubMed: 18808156]
23. Sturla SJ, Scott J, Lao Y, Hecht SS, Villalta PW. Mass spectrometric analysis of relative levels of pyridyloxobutyl adducts formed in the reaction of DNA with a chemically activated form of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Chem. Res. Toxicol.* 2005; 18:1048–1055. [PubMed: 15962940]
24. Chen L, Wang M, Villalta PW, Hecht SS. Liquid chromatography-electrospray ionization tandem mass spectrometry analysis of 7-ethylguanine in human liver DNA. *Chem. Res. Toxicol.* 2007; 20:1498–1502. [PubMed: 17887725]
25. Chung FL, Wang M, Hecht SS. Detection of exocyclic guanine adducts in hydrolysates of hepatic DNA of rats treated with N-nitrosopyrrolidine and in calf thymus DNA reacted with α -acetoxy-N-nitrosopyrrolidine. *Cancer Res.* 1989; 49:2034–2041. [PubMed: 2702646]
26. Patel JM, Wood JC, Leibman KC. The biotransformation of allyl alcohol and acrolein in rat liver and lung preparation. *Drug Metabol. Dispos.* 1980; 8:305–308.

27. Linhart I, Frantik E, Vodickova L, Vosmanska M, Smejkal J, Mitera J. Biotransformation of acrolein in rat: excretion of mercapturic acids after inhalation and intraperitoneal injection. *Toxicol Appl Pharmacol.* 1996; 136:155–160. [PubMed: 8560469]
28. Parent RA, Paust DE, Schrimpf MK, Talaat RE, Doane RA, Caravello HE, Lee SJ, Sharp DE. Metabolism and distribution of [2,3-¹⁴C]acrolein in Sprague-Dawley rats. II. Identification of urinary and fecal metabolites. *Toxicol. Sci.* 1998; 43:110–120. [PubMed: 9710952]
29. Winter SM, Weber GL, Gooley PR, MacKenzie NE, Sipes IG. Identification and comparison of the urinary metabolites of [1,2,3-¹³C₃]acrylic acid and [1,2,3-¹³C₃]propionic acid in the rat by homonuclear ¹³C nuclear magnetic resonance spectroscopy. *Drug Metab Dispos.* 1992; 20:665–672. [PubMed: 1358570]
30. Chung, FL.; Zhang, L.; Ocando, JE.; Nath, RG. Role of 1,*N*²-propanodeoxyguanosine adducts as endogenous DNA lesions in rodents and humans. In: Singer, B.; Bartsch, H., editors. *Exocyclic DNA Adducts in Mutagenesis and Carcinogenesis*. International Agency for Research on Cancer; Lyon, France: 1999. p. 45-54.
31. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. vol. 63. IARC; Lyon, FR: 1995. Acrolein; p. 337-372.
32. Chung FL, Young R, Hecht SS. Formation of cyclic 1,*N*²-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. *Cancer Res.* 1984; 44:990–995. [PubMed: 6318992]
33. Pan J, Davis W, Trushin N, Amin S, Nath RG, Salem N Jr, Chung FL. A solid-phase extraction/high-performance liquid chromatography-based ³²P-postlabeling method for detection of cyclic 1,*N*²-propanodeoxyguanosine adducts derived from enals. *Anal. Biochem.* 2006; 348:15–23. [PubMed: 16289438]
34. Nath RG, Ocando JE, Chung FL. Detection of 1,*N*²-propanodeoxyguanosine adducts as potential endogenous DNA lesions in rodent and human tissues. *Cancer Res.* 1996; 56:452–456. [PubMed: 8564951]
35. Nath RG, Ocando JE, Guttenplan JB, Chung FL. 1,*N*²Propanodeoxyguanosine adducts: Potential new biomarkers of smoking-induced DNA damage in human oral tissue. *Cancer Res.* 1998; 58:581–584. [PubMed: 9485001]
36. Emami A, Dyba M, Cheema AK, Pan J, Nath RG, Chung FL. Detection of the acrolein-derived cyclic DNA adduct by a quantitative ³²P-postlabeling/solid-phase extraction/HPLC method: blocking its artifact formation with glutathione. *Anal. Biochem.* 2008; 374:163–172. [PubMed: 18036548]
37. Chung FL, Nath RG, Nagao M, Nishikawa A, Zhou GD, Randerath K. Endogenous formation and significance of 1,*N*²-propanodeoxyguanosine adducts. *Mutat. Res. -Fund. Mol. M.* 1999; 424:71–81.
38. Liu X, Lovell MA, Lynn BC. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. *Anal. Chem.* 2005; 77:5982–5989. [PubMed: 16159131]
39. Zhang S, Villalta PW, Wang M, Hecht SS. Detection and quantitation of acrolein-derived 1,*N*²-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. *Chem. Res. Toxicol.* 2007; 20:565–571. [PubMed: 17385896]
40. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. vol. 71. IARC; Lyon, FR: 1999. Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide (Part Two); p. 1223-1230.
41. Carmella SG, Chen M, Zhang Y, Zhang S, Hatsukami DK, Hecht SS. Quantitation of acrolein-derived 3-hydroxypropylmercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry: effects of cigarette smoking. *Chem. Res. Toxicol.* 2007; 20:986–990. [PubMed: 17559234]
42. Ding YS, Blount BC, Valentin-Blasini L, Applewhite HS, Xia Y, Watson CH, Ashley DL. Simultaneous determination of six mercapturic acid metabolites of volatile organic compounds in human urine. *Chem Res Toxicol.* 2009; 22:1018–1025. [PubMed: 19522547]
43. Hormann U, Schwab M, Seefried S, Marx C, Zanger UM, Eichelbaum M, Mürdter TE. Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas

- chromatography-tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2003; 791:371–380.
44. Jiang H, Jiang J, Hu P, Hu Y. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. *J Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2002; 769:169–176.
45. Mirvish SS. Formation of *N*-nitroso compounds: chemistry, kinetics, and in vivo occurrence. *Toxicol. Appl. Pharmacol.* 1975; 31:325–351. [PubMed: 238307]
46. Mirvish SS. Role of *N*-nitroso compounds (NOC) and *N*-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. *Cancer Lett.* 1995; 93:17–48. [PubMed: 7600541]
47. Bartsch H, Ohshima H, Pignatelli B, Calmels S. Human exposure to endogenous *N*-nitroso compounds: quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder. *Cancer Surv.* 1989; 8:335–362. [PubMed: 2696584]
48. Singer, B.; Grunberger, D. *Molecular Biology of Mutagens and Carcinogens*. Plenum Press; New York: 1983. p. 45-96.
49. Lunn JC, Kuhnle G, Mai V, Frankenfeld C, Shuker DE, Glen RC, Goodman JM, Pollock JR, Bingham SA. The effect of haem in red and processed meat on the endogenous formation of *N*-nitroso compounds in the upper gastrointestinal tract. *Carcinogenesis.* 2007; 28:685–690. [PubMed: 17052997]
50. Joosen AM, Kuhnle GG, Aspinall SM, Barrow TM, Lecommandeur E, Azqueta A, Collins AR, Bingham SA. Effect of processed and red meat on endogenous nitrosation and DNA damage. *Carcinogenesis.* 2009; 30:1402–1407. [PubMed: 19498009]
51. Wang M, Yu N, Chen L, Villalta PW, Hochalter JB, Hecht SS. Identification of an acetaldehyde adduct in human liver DNA and quantitation as *N*²-ethyldeoxyguanosine. *Chem. Res. Toxicol.* 2006; 19:319–324. [PubMed: 16485909]
52. Zhang S, Villalta PW, Wang M, Hecht SS. Analysis of crotonaldehyde- and acetaldehyde-derived 1,*N*²-propanodeoxyguanosine adducts in DNA from human tissues using liquid chromatography-electrospray ionization-tandem mass spectrometry. *Chem. Res. Toxicol.* 2006; 19:1386–1392. [PubMed: 17040109]
53. De Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. *Mutagenesis.* 2004; 19:169–185. [PubMed: 15123782]
54. Dahlmann HA, Vaidyanathan VG, Sturla SJ. Investigating the biochemical impact of DNA damage with structure-based probes: abasic sites, photodimers, alkylation adducts, and oxidative lesions. *Biochemistry.* 2009; 48:9347–9359. [PubMed: 19757831]
55. Kunkel TA. Mutational specificity of depurination. *Proc Natl Acad. Sci. U. S. A.* 1984; 81:1494–1498. [PubMed: 6369329]

Figure 1.

Chromatograms obtained upon LC-ESI-MS/MS-SRM analysis of a hydrolysate of human liver DNA for the methyl esters of 7-CMGua and 7-CEGua. A Zorbax SB C18 column was used for the analysis. Shaded peaks correspond to the methyl esters of [$^{15}\text{N}_5$]7-CMGua internal standard (panel B); 7-CEGua (panel C); and [$^{15}\text{N}_5$]7-CEGua internal standard (panel D). No peak was observed corresponding to the methyl ester of 7-CMGua (panel A).

Figure 2. Chromatograms obtained upon LC-ESI-MS/MS-SRM analysis of a hydrolysate of human liver DNA for the methyl ester of 7-CEGua. A Synergi Polar-RP column was used for the analysis. Shaded peaks correspond to the methyl esters of A, 7-CEGua; and B, [$^{15}\text{N}_5$]7-CEGua internal standard.

Scheme 1.

Reactions which can produce 7-CMGua (**5**) and 7-CEGua (**13**). Carboxylic acids are shown in protonated form for consistency with adduct structures **5** and **13** which are detected in this form.

Scheme 2.

Method of analysis of human liver DNA for 7-CMGua and 7-CEGua.

Table 1

Relationship between added and measured amounts of 7-CEGua in calf thymus DNA.

Added ^a	Detected ^{b,c}	Accuracy (%)	Precision (CV, %)
20	22.3 ± 0.4	111	1.2
40	40.3 ± 3.5	100	8.7
80	81.0 ± 5.0	100	6.2
160	169 ± 3.6	106	2.1
320	328 ± 4.9	103	1.5

^a Added to 0.5 mg calf thymus DNA^b Amount present in calf thymus DNA was subtracted from each value 7-CEGua was detected as its methyl ester **21**.^c Mean ± S.D., N=3

Table 2Effects of *N*-acetylcysteine on formation of 7-CEGua in reactions of acrylic acid (**16**) with dGuo or DNA.^a

Reaction of 16 with	<i>N</i> -acetylcysteine (mM)	7-CEGua (fmol/μmol Gua) ^b	% Reduction
A. dGuo	0	5600	—
	1	4030	28
	2	3640	35
	5	1810	68
	10	1110	80
	<i>N</i> -acetylcysteine (mM)	7-CEGua (fmol/μmol Gua) ^c	% Reduction
B. DNA	0	1370	—
	5	308	77
	10	168	88
	20	305	77

^a Reactions were carried out with 0.3 mM **16** and dGuo (30 mg) or calf thymus DNA (30 mg) in 15 mL 0.1 M phosphate buffer (pH 7) at 37 °C for 24h.

^b dGuo contained 947 fmol/μmol 7-CEGua. This amount was subtracted from each value.

^c Calf thymus DNA contained 185 fmol/μmol 7-CEGua. This amount was subtracted from each value.

Table 37-(2'-Carboxyethyl)guanine in human liver DNA^{a,b}

Sample	Gender	Age	DNA Analyzed (mg)	7-CEGua (fmol/μmol Gua)
1	F	31	0.18	112
2	F	21	0.19	196
3	F	61	0.84	246
4	M	60	0.56	278
5	M	54	0.58	268
6	M	54	0.16	296
7	F	34	0.54	267
8	F	83	0.26	160
9	F	30	0.12	177
10	F	58	0.38	190
11	F	45	0.13	704
12	M	18	0.11	1120
13	F	51	0.17	769
14	F	50	0.20	326
15	F	51	0.95	17
16	F	38	0.12	1190
17	M	64	0.69	39
18	F	43	0.06	842
19	F	37	0.45	211
20	M	48	0.53	128
21	M	64	0.42	206
22	M	59	0.20	490
23	M	77	0.64	311
24	M	38	0.22	402

^a7-(2'-carboxyethyl)guanine (7-CEGua) was determined as its methyl ester **21**.^bNegative controls did not have detectable **21**. Positive control values were 172 ± 42 fmol/μmol Gua in calf thymus DNA samples run with each set.